SARS CoV-2 ( COVID-19) Current Pharmacotherapy for Mother and Infant

被引:0
|
作者
Thigpen, Jim [1 ]
机构
[1] East Tennessee State Univ, Bill Gatton Coll Pharm, Johnson City, TN USA
来源
NEONATAL NETWORK | 2021年 / 40卷 / 03期
关键词
bamlanivimab; COVID-19; dexamethasone; hydroxychloroquine/chloroquine; ivermectin; lopinavir/ritonavir; remdesivir; SARS-Cov-2; vaccines; PREGNANCY OUTCOMES; WOMEN;
D O I
10.1891/11-T-737
中图分类号
R47 [护理学];
学科分类号
1011 ;
摘要
The novel coronavirus disease 2019 (COVID-19), appeared in the United States over 1 year ago. This virus has a wide range of presentations, from being asymptomatic to causing severe acute respiratory syndrome, which can lead to death. It has led to a worldwide effort to find effective treatments, from repurposed medications to new discoveries, as well as the push to develop effective vaccines. As the race to fight this pandemic unfolds, this column provides what is currently available to combat this virus, how it has been utilized in the pregnant population, and what data have been made available about how these treatments affect fetal development and the neonate.
引用
收藏
页码:175 / 182
页数:8
相关论文
共 50 条
  • [21] Impact of SARS CoV-2 /COVID-19 infection on the course of advanced chronic liver disease and hepatocellular carcinoma
    Monika Pazgan-Simon
    Marta Kucharska
    Joanna Górka-Dynysiewicz
    Krzysztof Simon
    Pharmacological Reports, 2022, 74 : 1306 - 1314
  • [22] Role of COVID-19 Vaccines in SARS-CoV-2 Variants
    Zhou, Zhou
    Zhu, Yimiao
    Chu, Ming
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [23] The Complexity of SARS-CoV-2 Infection and the COVID-19 Pandemic
    da Silva Torres, Maria Karoliny
    Bichara, Carlos David Araujo
    de Almeida, Maria de Nazare do Socorro
    Vallinoto, Mariana Cayres
    Queiroz, Maria Alice Freitas
    Vallinoto, Izaura Maria Vieira Cayres
    dos Santos, Eduardo Jose Melo
    de Carvalho, Carlos Alberto Marques
    Vallinoto, Antonio Carlos R.
    FRONTIERS IN MICROBIOLOGY, 2022, 13
  • [24] COVID-19 vaccines and decreased transmission of SARS-CoV-2
    A. Vitiello
    F. Ferrara
    V. Troiano
    R. La Porta
    Inflammopharmacology, 2021, 29 : 1357 - 1360
  • [25] COVID-19 vaccines and decreased transmission of SARS-CoV-2
    Vitiello, A.
    Ferrara, F.
    Troiano, V
    La Porta, R.
    INFLAMMOPHARMACOLOGY, 2021, 29 (05) : 1357 - 1360
  • [26] COVID-19 and SARS-CoV-2 Variants: Current Challenges and Health Concern
    Zeyaullah, Md.
    AlShahrani, Abdullah M.
    Muzammil, Khursheed
    Ahmad, Irfan
    Alam, Shane
    Khan, Wajihul Hasan
    Ahmad, Razi
    FRONTIERS IN GENETICS, 2021, 12
  • [27] The immune response to SARS-CoV-2 and COVID-19 immunopathology -- Current perspectives
    Boechat, J. L.
    Chora, I.
    Morais, A.
    Delgado, L.
    PULMONOLOGY, 2021, 27 (05): : 423 - 437
  • [28] Impact of SARS CoV-2 /COVID-19 infection on the course of advanced chronic liver disease and hepatocellular carcinoma
    Pazgan-Simon, Monika
    Kucharska, Marta
    Gorka-Dynysiewicz, Joanna
    Simon, Krzysztof
    PHARMACOLOGICAL REPORTS, 2022, 74 (06) : 1306 - 1314
  • [29] SARS-CoV-2 and the brain: A review of the current knowledge on neuropathology in COVID-19
    Maiese, Aniello
    Manetti, Alice Chiara
    Bosetti, Chiara
    Del Duca, Fabio
    La Russa, Raffaele
    Frati, Paola
    Di Paolo, Marco
    Turillazzi, Emanuela
    Fineschi, Vittorio
    BRAIN PATHOLOGY, 2021, 31 (06)
  • [30] Current and emerging immunomodulators for treatment of SARS-CoV2 infection (COVID-19)
    McCarthy, Matthew W.
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (05) : 623 - 628